Fortrea’s first quarter results were well received by investors, as the company exceeded Wall Street expectations on both revenue and non-GAAP earnings. Management attributed this performance to improved commercial execution in its core clinical research services, especially a rebound in biotech client activity and a higher book-to-bill ratio for the third straight quarter. CEO Anshul Thakral emphasized the impact of deliberate efforts to diversify the customer base, with notable wins among early-stage and publicly listed biotech firms, while CFO Jill McConnell highlighted operational discipline and ongoing cost-optimization initiatives as key contributors to margin expansion.
Is now the time to buy FTRE? Find out in our full research report (it’s free for active Edge members).
Fortrea (FTRE) Q1 CY2026 Highlights:
- Revenue: $636.5 million vs analyst estimates of $627.5 million (2.3% year-on-year decline, 1.4% beat)
- Adjusted EPS: $0.16 vs analyst estimates of $0.05 (significant beat)
- Adjusted EBITDA: $47 million vs analyst estimates of $34.61 million (7.4% margin, 35.8% beat)
- The company reconfirmed its revenue guidance for the full year of $2.6 billion at the midpoint
- EBITDA guidance for the full year is $205 million at the midpoint, above analyst estimates of $201.8 million
- Market Capitalization: $1.42 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Fortrea’s Q1 Earnings Call
- Patrick Donnelly (Citi) asked about biotech momentum and the competitive environment. CEO Anshul Thakral explained the recovery in biotech demand and highlighted increased new-to-Fortrea biotech activity as evidence of successful commercial execution.
- Elizabeth Anderson (Evercore) inquired about China as a growth area. Thakral noted China’s ongoing strength is rooted in an established presence and expanding customer base, with no major incremental investment planned beyond continued operational focus.
- Max Smock (William Blair) questioned whether recent gains reflect market recovery or share gains. Thakral said increased activity is mostly due to improved commercial reach, with win rates and new client additions both trending favorably.
- Eric Coldwell (Baird) asked about the mix of bookings and the impact of “rescue” projects. Thakral confirmed a shift toward full-service outsourcing wins and noted rescue projects are routine but not a trend for the quarter.
- Charles Rhyee (TD Cowen) raised questions on AI’s impact on pricing and margins. Thakral emphasized it’s early stages, with AI currently seen as a tool to enhance efficiency and decision-making rather than a driver of lower pricing.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be monitoring (1) the continued pace and quality of biotech client wins and whether commercial traction remains robust; (2) early adoption and measurable impact of the FIT platform on operational efficiency and trial timelines; and (3) the realization of additional cost savings and margin gains as rightsizing initiatives mature. Sustained improvement in backlog conversion and any signs of changing competitive dynamics will also be important to track.
Fortrea currently trades at $14.99, up from $12.25 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
